Orbit Genomics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $2.5M

Overview

Orbit Genomics is a private, pre-revenue diagnostics company pioneering the analysis of repetitive DNA through its AI-driven OrbiSeq™ platform. Its lead product, OrbiSeq-L, is a non-invasive blood test designed to accurately diagnose early-stage lung cancer in patients with indeterminate pulmonary nodules, aiming to replace invasive biopsies. Founded in 2018 as a collaboration between Dr. Harold 'Skip' Garner and Ventac Partners, the company is establishing a scalable genomic foundation with applications across oncology, cardiology, neurology, and longevity. It recently won a national startup competition and is building its team, including a new Laboratory Director, to advance its diagnostic pipeline.

OncologyCardiovascularNeurological

Technology Platform

AI-powered OrbiSeq™ platform for genome-wide analysis of repetitive DNA (short tandem repeats/STRs) to enable non-invasive diagnosis and risk stratification.

Funding History

1

Total raised:$2.5M

Seed$2.5MY CombinatorJun 15, 2020

Opportunities

The immediate opportunity is addressing the large, unmet need in diagnosing indeterminate pulmonary nodules with a non-invasive blood test, potentially replacing costly and risky biopsies.

Long-term, the platform technology allows for rapid expansion into other cancers, cardiovascular, and neurological diseases, as well as the growing longevity and preventive health market.

Risk Factors

Key risks include the unproven clinical utility of STR analysis at scale, the challenge of securing insurance reimbursement for a novel diagnostic, and intense competition in the liquid biopsy space from companies using more established genomic biomarkers.

Competitive Landscape

Orbit competes in the crowded liquid biopsy and early cancer detection space against well-capitalized players like Guardant Health, Grail, and Freenome. Its differentiation hinges on its unique focus on repetitive DNA (STRs) rather than somatic mutations or methylation, which is an unproven but potentially disruptive approach. It must demonstrate superior accuracy or cost-effectiveness to gain market share.

More companies in Diagnostics & Precision Medicine →More companies in United States →